Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

Main objective The main objective of the study is to assess the virological efficacy of a Dolutegravir-based first-line ART in use under real-life conditions in national programs in resource-limited settings in patients infected with HIV-1 and initially under a NNRTI-based first-line, and determine the impact of NRTI resistance on the success of the new strategy. Secondary objectives * Determine the level of virological suppression (HIV-1 RNA \

Inclusion Criteria: * Aged 18 years or over. * Infected with HIV-1. * On an NNRTI-based first-line for at least 6 months. * Initiating a new 1st line ART based on DTG according to national recommendations. * Agree to participate in the study and provide free, written and informed consent. Exclusion Criteria: * Infection with HIV-2 or HIV1+2. * Ongoing participation in another virological study on HIV infection